Switzerland: Deferred Hep C therapy in MSM with HIV increases risk for mortality

Hepatitis C (HCV) is a leading cause of morbidity and mortality in people who live with HIV. In many countries, access to drugs to treat HCV is restricted to individuals with advanced liver disease. Using the Swiss HIV Cohort longitudinal study, the research goal was to estimate the long term impact of deferring HCV treatment for men who have sex with men (MSM) who are coinfected with HIV and often have multiple risk factors for liver disease progression.

The study found that early treatment of Hepatitis C could reduce replication of the disease, thereby reducing the risk of transmission. Additionally they determined that delayed treatment increased liver-related morbidity and mortality. Read more via Journal of Hepatology